ImpactOS
See an example

MEDICINES FOR EUROPE

Trade and business associations · Belgium

In these lists: Medicines

Declared lobbying cost
€500,000 – €599,999 Financial year 01/2024-12/2024
Commission meetings
19
Full-time staff on EU lobbying
7.95
European Parliament access passes
8
EU funding received
€93,300
Registered since
16 Jun 2009
Public records onlyWhat this means

Every profile, record and figure comes from documents published by EU institutions, national authorities, courts, ethics bodies, the EU Transparency Register or established news outlets. We use no leaks, private data or anonymous tips. AI helps us gather and cross-check sources but never decides anyone's guilt: each record keeps its exact legal status and links to its source, so you can check it yourself

Registering is a legal transparency duty, not a sign of wrongdoing. Budgets and meetings show access, not influence on any particular decision. Register figures as declared on 30 Jun 2026

Fields of interest

Budget, Business and industry, Climate action, Communication, Competition, Consumers, Customs, Digital economy and society, Economy, finance and the euro, Education and training, Employment and social affairs, Enlargement, Environment, European neighbourhood policy, External relations, Foreign affairs and security policy, Humanitarian aid and civil protection, Institutional affairs, International co-operation and development, Public health, Regional policy, Research and innovation, Single market, Taxation, Trade

Medicines and food topics they name

EU medicines law, Critical medicines, Orphan and paediatric medicine incentives

EU laws and policies they declare following3
  • Medicines for Europe plays an important consultative part in European healthcare policy-making and provides key educational role for its members. Medicines for Europe and its members work with Europe…
  • Medicines for Europe is engaged to work on a variety of EU pharmaceutical policies and legislative proposals, which include, but is not limited to:
  • the implementation of the pharmaceutical and IP strategies; The implementation of the SPC Manufacturing Waiver, which was introduced in July 2019; the broad review of the pharmaceutical incentives (e…

Meetings with the Commission

Meetings with Commissioners or their Cabinets since 1 December 2024, as the Commission publishes them

  1. With the Commissioner

    Olivér Várhelyi

    Sustainability of European pharmaceutical manufacturing

    Published record
  2. With the Cabinet

    Olivér Várhelyi

    Sustainability of European pharmaceutical manufacturing

    Published record
  3. With the Cabinet

    Olivér Várhelyi

    Preventive health and early detection

    Published record
  4. With the Commissioner

    Olivér Várhelyi

    Health industry roundtable

    Published record
  5. With the Cabinet

    Olivér Várhelyi

    Health industry roundtable

    Published record
  6. With the Commissioner

    Olivér Várhelyi

    Health industry roundtable

    Published record
  7. With the Cabinet

    Olivér Várhelyi

    Health industry roundtable

    Published record
  8. With the Commissioner

    Olivér Várhelyi

    Current pharma matters

    Published record
  9. With the Cabinet

    Jessika Roswall

    UWWTD- the Urban Wastewater Treatment Directive

    Published record
  10. With the Commissioner

    Olivér Várhelyi

    Biotech Act, Pharma package, CMA

    Published record

See all 19 meetings

Official entries

Checked against sources on 11 Nov 2026